• 1
    Vora AJ, Toh CH, Peel J, et al. Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration. Br J Haematol 1994; 86: 180182.
  • 2
    Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells after administration of G-CSF. Blood 1993; 81: 31583163.
  • 3
    Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony-stimulating factor “mobilized” peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 20312038.
  • 4
    Lane TA, Law P, Maruyama M, et al. Harvesting and enrichment of HPC mobilized into the peripheral blood of normal donors by GM-CSF or G-CSF: potential role in allogeneic transplantation. Blood 1995; 85: 275282.
  • 5
    Watts MJ, Sullivan AM, Jamieson E, et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535546.
  • 6
    Gazitt Y, Freytes CO, Callander N, et al. Successful PBSC mobilization with high dose G-CSF for patients failing a first round of mobilization. J Hematother 1999; 8: 173183.
  • 7
    Peters WP, Rosner G, Ross M, et al. Comparative effect of GM-CSF and G-CSF on priming of peripheral blood progenitor cells for use with autologous bone marrow after high dose chemotherapy. Blood 1993; 81: 17091719.
  • 8
    Lane TA, Ho AD, Bashey A, et al. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. Transfusion 1999; 39: 3947
  • 9
    Gazitt Y. Immunological profiles of effector cells and peripheral blood stem cells mobilized with different growth factors. Stem Cells 2001; 18: 390398.
  • 10
    Gazitt Y. Recent developments in the regulation of peripheral blood stem cell mobilization. J Hematother Stem Cell Res 2001; 10: 229236
  • 11
    Gazitt Y. Comparison between granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the mobilization of peripheral blood stem cells. Curr Opin Hematol 2002; 9: 190198.
  • 12
    Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687694.
  • 13
    Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m (null) mice. Leukemia 2002; 16: 19922003.
  • 14
    Lapidot T, Petit I. Current understanding of stem cell mobilization. The roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002; 30: 973981.
  • 15
    Sharp JG, Joshi SS, Armitage JO, et al. Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by aculture technique. Blood 1992; 79: 10741080.
  • 16
    Dreyfus F, Ribrag V, Leblond V, et al. Detection of malignant B cells in peripheral blood stem cell collections after chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 1995; 15: 707712.
  • 17
    Gazitt Y, Shaughnessy P, Liu Q. Differential mobilization of CD34+ stem cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with cyclophosphamide with different growth factors. J. Hematother Stem Cell Res 2001; 10: 167176.
  • 18
    Gazitt Y, Reading C, Hoffman R, et al. Purified CD34+ LinThy+ stem cells do not contain clonal myeloma cells. Blood 1995; 86: 381389.
  • 19
    Gazitt Y, Tian E, Barlogie B, et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and GM-CSF. Blood 1996; 87: 805811.
  • 20
    Gazitt Y, Reading C. Autologous transplantation with tumor-free graft: a model for multiple myeloma patients. Leuk Lymphoma 1996; 27: 202212.
  • 21
    Tricot G, Gazitt Y, Leemhuis T, et al. Collection, engraftment kinetics and tumor contamination of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 1998; 91: 44894495.
  • 22
    Moss TJ, Cairo M, Santana VM, et al. Clonogenic circulating BM cells: implications regarding peripheral stem cell transplantation. Blood 1994; 83: 30853090.
  • 23
    Brugger W, Bross KJ, Glatt M, et al. Mobilization of tumor cells and hematopoietic stem cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636640.
  • 24
    Shpall EJ, Jones R. Release of tumor cells from bone marrow. Blood 1994; 83: 623628.
  • 25
    Robledo MM, Sanz-Rodriguez F, Hidalgo A, et al. Differential use of VLA-4 and −5 integrins by hematopoietic precursors and myeloma cells to adhere to bone marrow stroma. J Biol Chem 1998; 273: 1205612060.
  • 26
    Okada T, Hawley RG, Kodaka M, et al. Significance of VLA-4-VCAM-1 interaction and CD44 for transendothelial invasion in a bone marrow metastatic myeloma model. Clin Exp Metastasis 1999; 17: 623629.
  • 27
    Damiano JS, Cress AE, Hazlehurst LA, et al. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 16581667.
  • 28
    Choi SJ, Oba Y, Gazitt Y, et al. Antisense inhibition of macrophage inflammatory protein-1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001; 108: 18331841.
  • 29
    Sanz-Rodríguez F, Hidalgo A, Teixidó J. Chemokine stromal cell-derived factor-1 modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001; 97: 346351.
  • 30
    Libura J, Drukala J, Majka M, et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 2002; 100: 25972606.
  • 31
    Taichman RS, Cooper C, Keller ET, et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 18321837.
  • 32
    Schrader AJ, Lechner O, Templin M, et al. CXCR4/CXCL12 expression and signaling in kidney cancer. Br J Cancer 2002; 86: 12501256.
  • 33
    Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 2002; 118: 915922.
  • 34
    Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath BM stromal cells. Blood 1999; 94: 36583667.
  • 35
    Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma 2002; 43: 461466.
  • 36
    Majka M, Pituch-Noworolska A, Drukala J, et al. SDF-1/ CXCR4 interactions are crucial in the migration and survival of chronic lymphocytic leukemia cells in the bone marrow microenvironment. Blood 2002; 100: 381a.
  • 37
    Durig J, Schmucker U, Duhrsen U. Differential expression of chemokine receptors in B cell malignancies. Leukemia 2001; 15: 752756.
  • 38
    Donnard M, Trimoreau F, Jaccard A, et al. Chemokines receptor expression profile in low grade non Hodgkin lymphoma with leukemic phase. Blood 2002; 100: 349a.
  • 39
    Durig J, Rosenthal C, Elmaagacli A, et al. Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+ haemopoietic cells. Leukemia 2000; 14: 16521660.
  • 40
    Mohle R, Schittenhelm M, Failenschmid C, et al. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br J Haematol 2000; 110: 563572.
  • 41
    Shen W, Bendall LJ, Gottlieb DJ, et al. The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp Hematol 2001; 29: 14391447.
  • 42
    Hideshima T, Chauhan D, Hayashi T, et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther 2002; 1: 539544.
  • 43
    Moller C, Stromberg T, Juremalm M, et al. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 2003; 17: 203210.
  • 44
    Bertolini F, Dell'Agnola C, Mancuso P, et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 2002; 62: 31063112.
  • 45
    Lagneaux L, Delforge A, Dejeneffe M, et al. Antagonists of the chemokine receptor CXCR4 block chemotaxis and inhibit stromal dependent proliferation of acute lymphoblastic leukemia cells. Blood 2002; 100: 762a.
  • 46
    Boehmler AM, Kuci S, Seitz G, et al. In vitro and preclinical activity of the novel AMD3100 CXCR4 antagonist in lymphoma models. Blood 2002; 100: 579a.
  • 47
    Schwarz MK, Wells TN. New therapeutics that modulate chemokine networks. Nat Rev Drug Discov 2002; 1: 347358.
  • 48
    Gazitt Y, Akay C, Thomas C, et al. The role of adhesion molecules and CXCR4/SDF-1 axis in mobilization of malignant myeloma cells. Cancer Res 2003, 94: 524a.
  • 49
    Gazitt Y, Shaughnessy P, Liu Q. Expression of adhesion molecules on CD34+ cells in mobilized peripheral blood of non-Hodgkin's lymphoma patients. Stem Cells 2001; 19: 134143.
  • 50
    Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma pts and is not cytotoxic to hematopoietic stem cells. Leukemia 1999; 13: 18171824.
  • 51
    Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9 and synergy with APO2/TRAIL. Blood 2003; 101: 40784087.
  • 52
    Gazitt Y, Liu Q. Plasma levels of SDF-1 and expression of SDF-1 receptor on CD34+ cells in mobilized peripheral blood of non-Hodgkin's lymphoma patients. Stem Cells 2001; 19: 3745.
  • 53
    Forster R, Kremmer E, Schubel A, et al. Intracellular and surface expression of HIV-1 co-receptor CXCR4/fusin on various leukocytes subsets: rapid internalization and recycling upon activation. J Immunol 1998; 160: 15221531.
  • 54
    Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999; 283: 845848.
  • 55
    Peled A, Kollet O, Ponomaryov T, et al. The chemokine SDF-1 activates the integrin LFA-1, VLA-4, and VLA-5 on immature human CD34+ cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000; 95: 32893296.
  • 56
    Odemis V, Moepps B, Gierschik P, et al. Interleukin-6 and cAMP induce stromal cell-derived factor-1 chemotaxis in astroglia by up-regulating CXCR4 cell surface expression. J Biol Chem 2002; 277: 3980139808.
  • 57
    Jourdan M, De Vos J, Mechti N, et al. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death Diff 2000; 7: 12441252.
  • 58
    Chatterjee M, Honemann D, Lentzsch S, et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood 2002; 100: 33113318.
  • 59
    Lauta VM. A review of the cytokine network in multiple myeloma. Cancer 2003; 97: 24402452.
  • 60
    Bisping G, Leo R, Wenning D, et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003; 101: 27752783.
  • 61
    Mudry RE, Fortney JE, York T, et al. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 2000; 96: 19261932.
  • 62
    Gibson LF. Survival of B lineage leukemic cells: signals from the bone marrow microenvironment. Leuk Lymphoma 2002; 43: 1927.
  • 63
    Landowski TH, Olashaw NE, Agrawal D, et al. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappaB (RelB/p50) in myeloma cells. Oncogene 2003; 22: 24172421.
  • 64
    Dalton WS. The tumor microenvironment: focus on myeloma. Cancer Treat Rev 2003; 29(suppl 1):1119.